Korean Circ J.  2017 Mar;47(2):179-181. 10.4070/kcj.2017.0011.

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?

• Han JW

• KMID: 2377457
• DOI: http://doi.org/10.4070/kcj.2017.0011

Abstract

No abstract available.

MeSH Terms

Immunoglobulins*
Mucocutaneous Lymph Node Syndrome*
Immunoglobulins

Reference

1. Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1983; 2:1359.

2. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981; 1:1228–1231.

3. Burns JC, Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol. 2015; 11:819–825.

4. Negi VS, Elluru S, Sibéril S. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007; 27:233–245.

5. Bayry J, Negi VS, Kaveri SV. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol. 2011; 7:349–359.

6. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013; 13:176–189.

7. Franco A, Touma R, Song Y, et al. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity. 2014; 47:95–104.

8. Hsu CH, Chen MR, Hwang FY, et al. Efficacy of plasmin-treated intravenous gamma-globulin for therapy of Kawasaki syndrome. Pediatr Infect Dis J. 1993; 12:509–512.

9. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta paediatrica Japonica. 1991; 33:805–810.

10. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986; 315:341–347.

11. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Circulation. 2004; 110:2747–2771.

12. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006; 149:237–240.

13. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007; 166:131–137.

14. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113:2606–2612.

15. Chang LS, Lo MH, Li SC, Yang MY, Hsieh KS, Kuo HC. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease. Oncotarget. 2017; 8:2044–2052.

16. Dahdah N, Siles A, Fournier A, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol. 2009; 30:810–817.

17. Eladawy M, Dominguez SR, Anderson MS, Glode MP. Abnormal liver panel in acute Kawasaki disease. Pediatr Infect Dis J. 2011; 30:141–144.

18. Lim GW, Lee M, Kim HS, Hong YM, Sohn S. Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion in kawasaki disease. Korean Circ J. 2010; 40:507–513.

19. Kim BY, Kim D, Kim YH, et al. Non-responders to intravenous immunoglobulin and coronary artery dilatation in Kawasaki disease: predictive parameters in Korean children. Korean Circ J. 2016; 46:542–549.

20. Wang Y, Li Z, Hu G, et al. Unique molecular patterns uncovered in Kawasaki disease patients with elevated serum gamma glutamyl transferase levels: implications for intravenous immunoglobulin responsiveness. PLoS One. 2016; 11:e0167434.

21. Okuma Y, Suda K, Nakaoka H, et al. Serum tenascin-C as a novel predictor for risk of coronary artery lesion and resistance to intravenous immunoglobulin in Kawasaki disease- a multicenter retrospective study. Circ J. 2016; 80:2376–2381.

22. Bonilla FA. Intravenous and subcutaneous immunoglobulin G replacement therapy. Allergy Asthma Proc. 2016; 37:426–431.

23. Marie I, Chérin P, Michallet M, et al. Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice. Rev Med Interne. 2016; [Epub ahead of print]. DOI: 10.1016/j.revmed.2016.10.390.

24. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007; 6:257–259.

25. Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006; 6:535–542.

26. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang. 2010; 98:12–28.

27. Stein MR, Wasserman RL, Moy J. Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency. Lymphosign J. 2015; 2:21–29.

28. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946; 68:459–475.

29. Melin JL, Oncley M, Richert DA. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949; 71:541–550.

30. Yoon KL, Lee HY, Yu JJ, et al. Multicenter, single-arm, phase IV study to evaluate the efficacy and safety of the combined therapy of aspirin and high-dose “IVIG-SN” for pediatric patients with Kawasaki disease. Korean Circ J. 2017; 47:209–214.

31. Durongpisitkul K, Soongswang J, Laohaprasitiporn D. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol. 2003; 24:145–148.

32. Clinically useful predictors of resistance to intravenous immunoglobulin and prognosis of coronary artery lesions in patients with incomplete Kawasaki disease. Korean Circ J. 2014; 44:328–335.

33. Yeo Y, Kim T, Ha K, et al. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr. 2009; 168:157–162.